Johanna
Hynninen
Docent, Department of Clinical Medicine
Obstetrics and Gynaecology
Adjunct professor, MD, Gynecologic oncologist
https://sites.utu.fi/ovariancancer/ https://www.deciderproject.eu
Contact
Links
Areas of expertise
gynaecologic oncology
ovarian cancer
Publications
Extracellular matrix proteins increase invasive growth and chemotherapy resistance of ovarian cancer cells (2020)
Clinical Cancer Research
(Muu (O2))
Exploratory Analysis of CA125-MGL and –STn Glycoforms in the Differential Diagnostics of Pelvic Masses (2020)
The Journal of Applied Laboratory Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer (2020)
Clinical Cancer Research
(Muu (O2))
The feasibility of [F-18]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study (2020)
EJNMMI Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research Sep 13-16, 2019 Atlanta, GA, USA Abstracts (2020)
Clinical Cancer Research
(Muu (O2))
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer (2020)
Gynecologic Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors (2020)
Journal of Pathology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets (2020)
Bioinformatics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
RNA-seq analysis of high-grade serous ovarian cancer patients before and after chemotherapy reveals chemoresistance-associated genes and pathways (2020)
Clinical Cancer Research
(Muu (O2))
Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 (2020)
Communications Biology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))